Report on the 8th international symposium on the role of soy in health promotion and chronic disease prevention and treatment

Journal of Nutrition

Volumn 139, Issue 4, 2009, Pages

  Messina, Mark ^a,b   Watanabe, Shaw ^c   Setchell, Kenneth D R ^d  

^a Nutrition Matters Inc   (United States)

^b LOMA LINDA UNIVERSITY   (United States)

^c NATIONAL INSTITUTE OF HEALTH AND NUTRITION   (Japan)

^d UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBENZAMIDINE; AMILORIDE; DAIDZEIN; EQUOL; GENISTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOFLAVONE; PHYTOSTEROL; PLACEBO; SOYBEAN PROTEIN; TAMOXIFEN; CHOLESTEROL; HORMONE;

BONE DENSITY; BREAST CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; DIETARY INTAKE; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG ELIMINATION; DRUG SAFETY; ENDOMETRIOSIS; FOOD INTAKE; HEALTH PROMOTION; HIP FRACTURE; HORMONAL REGULATION; HOT FLUSH; HUMAN; INTRADUCTAL CARCINOMA; ISCHEMIC HEART DISEASE; MASTECTOMY; NONHUMAN; PARTIAL MASTECTOMY; POSTMENOPAUSE OSTEOPOROSIS; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; SOCIOECONOMICS; SOYBEAN; ANIMAL; BLOOD; BREAST TUMOR; CHRONIC DISEASE; DIET THERAPY; FEMALE; MALE; MENOPAUSE; METABOLISM; METHODOLOGY; PHYSIOLOGY; REPRODUCTION;

GLYCINE MAX;

ANIMALS; BONE DENSITY; BREAST NEOPLASMS; CHOLESTEROL; CHRONIC DISEASE; FEMALE; HEALTH PROMOTION; HORMONES; HUMANS; MALE; MENOPAUSE; REPRODUCTION; SOYBEANS;

EID: 64049103080     PISSN: 00223166     EISSN: 15416100     Source Type: Journal    
DOI: 10.3945/jn.108.104182     Document Type: Conference Paper

References (69)

1. Setchell KDR, Brown NM, Lydeking-Olsen E. The clinical importance of the metabolite equol-a clue to the effectiveness of soy and its isoflavones. J Nutr. 2002;132:3577-84.
2. Franke AA, Custer LJ, Cerna CM, Narala KK. Quantitation of phytoestrogens in legumes by HPLC. J Agric Food Chem. 1994;42: 1905-13.
3. Cutler GJ, Nettleton JA, Ross JA, Harnack LJ, Jacobs DR Jr, Scrafford CG, Barraj LM, Mink PJ, Robien K. Dietary flavonoid intake and risk of cancer in postmenopausal women: the Iowa Women's Health Study. Int J Cancer. 2008;123:664-71.
4. van Erp-Baart MA, Brants HA, Kiely M, Mulligan A, Turrini A, Sermoneta C, Kilkkinen A, Valsta LM. Isoflavone intake in four different European countries: the VENUS approach. Br J Nutr. 2003;89:Suppl 1:S25-30.
5. Messina M, Nagata C, Wu AH. Estimated Asian adult soy protein and isoflavone intakes. Nutr Cancer. 2006;55:1-12.
6. Murphy PA, Barua K, Hauck CC. Solvent extraction selection in the determination of isoflavones in soy foods. J Chromatogr B Analyt Technol Biomed Life Sci. 2002;777:129-38.
7. Hwang CS, Kwak HS, Lim HJ, Lee SH, Kang YS, Choe TB, Hur HG, Han KO. Isoflavone metabolites and their in vitro dual functions: they can act as an estrogenic agonist or antagonist depending on the estrogen concentration. J Steroid Biochem Mol Biol. 2006;101:246-53.
8. Sarkar FH, Li Y. Soy isoflavones and cancer prevention. Cancer Invest. 2003;21:744-57.
9. Baldi F, Mantovani A. A new database for food safety: EDID (Endocrine disrupting chemicals-Diet Interaction Database). Ann Ist Super Sanita. 2008;44:57-63.
10. Phillips KP, Tanphaichitr N. Human exposure to endocrine disrupters and semen quality. J Toxicol Environ Health B Crit Rev. 2008;11:188-220.
11. Oseni T, Patel R, Pyle J, Jordan VC. Selective estrogen receptor modulators and phytoestrogens. Planta Med. 2008;74:1656-65.
12. Brzezinski A, Debi A. Phytoestrogens: the ''natural'' selective estrogen receptor modulators? Eur J Obstet Gynecol Reprod Biol. 1999;85:47-51.
13. Messina M, Barnes S. The role of soy products in reducing risk of cancer. J Natl Cancer Inst. 1991;83:541-6.
14. Messina M, McCaskill-Stevens W, Lampe JW. Addressing the soy and breast cancer relationship: review, commentary, and workshop proceedings. J Natl Cancer Inst. 2006;98:1275-84.
15. Warri A, Saarinen NM, Makela S, Hilakivi-Clarke L. The role of early life genistein exposures in modifying breast cancer risk. Br J Cancer 2008.
16. Lamartiniere CA, Zhao YX, Fritz WA. Genistein: mammary cancer chemoprevention, in vivo mechanisms of action, potential for toxicity and bioavailability in rats. J Women's Cancer. 2000;2:11-19.
17. Pisani P, Bray F, Parkin DM. Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int J Cancer. 2002;97:72-81.
18. Ohsumi S, Sakamoto G, Takashima S, Koyama H, Shin E, Suemasu K, Nishi T, Nakamura S, Iino Y, et al. Long-term results of breast- conserving treatment for early-stage breast cancer in Japanese women from multicenter investigation. Jpn J Clin Oncol. 2003;33:61-7.
19. Helferich WG, Andrade JE, Hoagland MS. Phytoestrogens and breast cancer: a complex story. Inflammopharmacology 2008;16:219-26.
20. Messina MJ, Wood CE. Soy isoflavones, estrogen therapy, and breast cancer risk: analysis and commentary. Nutr J. 2008;7:17.
21. Doyle C, Kushi LH, Byers T, Courneya KS, Demark-Wahnefried W, Grant B, McTiernan A, Rock CL, Thompson C, et al. Nutrition and physical activity during and after cancer treatment: an American Cancer Society guide for informed choices. CA Cancer J Clin. 2006;56:323-53.
22. Chavarro JE, Rich-Edwards JW, Rosner B, Willett WC. A prospective study of dairy foods intake and anovulatory infertility. Hum Reprod. 2007;22:1340-7.
23. Poulsen RC, Kruger MC. Soy phytoestrogens: impact on postmeno- pausal bone loss and mechanisms of action. Nutr Rev. 2008;66:359-74.
24. Messina M, Ho S, Alekel DL. Skeletal benefits of soy isoflavones: a review of the clinical trial and epidemiologic data. Curr Opin Clin Nutr Metab Care. 2004;7:649-58.
25. Ma DF, Qin LQ, Wang PY, Katoh R. Soy isoflavone intake increases bone mineral density in the spine of menopausal women: meta-analysis of randomized controlled trials. Clin Nutr. 2008;27:57-64.
26. Marini H, Minutoli L, Polito F, Bitto A, Altavilla D, Atteritano M, Gaudio A, Mazzaferro S, Frisina A, et al. Effects of the phytoestrogen genistein on bone metabolism in osteopenic postmenopausal women: a randomized trial. Ann Intern Med. 2007;146:839-47.
27. Zhang X, Shu XO, Li H, Yang G, Li Q, Gao YT, Zheng W. Prospective cohort study of soy food consumption and risk of bone fracture among postmenopausal women. Arch Intern Med. 2005;165:1890-5.
28. Murkies AL, Lombard C, Strauss BJ, Wilcox G, Burger HG, Morton MS. Dietary flour supplementation decreases post-menopausal hot flushes: effect of soy and wheat. Maturitas. 1995;21:189-95.
29. Nelson HD. Postmenopausal estrogen for treatment of hot flashes: clinical applications. JAMA. 2004;291:1621-5.
30. Lethaby AE, Brown J, Marjoribanks J, Kronenberg F, Roberts H, Eden J. Phytoestrogens for vasomotor menopausal symptoms. Cochrane Database Syst Rev. 2007;CD001395.
31. Howes LG, Howes JB, Knight DC. Isoflavone therapy for menopausal flushes: a systematic review and meta-analysis. Maturitas. 2006;55: 203-11.
32. Williamson-Hughes PS, Flickinger BD, Messina MJ, Empie MW. Isoflavone supplements containing predominantly genistein reduce hot flash symptoms: a critical review of published studies. Menopause. 2006;13:831-9.
33. Messina M, Hughes C. Efficacy of soyfoods and soybean isoflavone supplements for alleviating menopausal symptoms is positively related to initial hot flush frequency. J Med Food. 2003;6:1-11.
34. Anderson JW, Johnstone BM, Cook-Newell ME. Meta-analysis of the effects of soy protein intake on serum lipids. N Engl J Med. 1995;333:276-82.
35. Food Labeling: Health Claims; Soy Protein and Coronary Heart Disease. Fed Register. 1999;64:57699-57733.
36. Erdman JW Jr. Soy protein and cardiovascular disease: A statement for healthcare professionals from the nutrition committee of the AHA. Circulation. 2000;102:2555-9.
37. Sacks FM, Lichtenstein A, Van Horn L, Harris W, Kris-Etherton P, Winston M. Soy protein, isoflavones, and cardiovascular health: an American Heart Association Science Advisory for professionals from the Nutrition Committee. Circulation. 2006;113:1034-44.
38. Balk E, Chung M, Chew P, Ip S, Raman G, Kuplenick B, Tatsioni A, Sun Y, Wolk B, et al. Effects of soy on health outcomes. Evidence report/ technology assessment No. 126 (prepared by Tufts-New England Medical Center Evidence-based Practice Center under Contract No. 290-02-0022.) AHRQ Publication No. 05-E024-2. Rockville, MD: Agency for Healthcare Research and Quality, July 2005.
39. Zhan S, Ho SC. Meta-analysis of the effects of soy protein containing isoflavones on the lipid profile. Am J Clin Nutr. 2005;81:397-408.
40. Taku K, Umegaki K, Sato Y, Taki Y, Endoh K, Watanabe S. Soy isoflavones lower serum total and LDL cholesterol in humans: a meta-analysis of 11 randomized controlled trials. Am J Clin Nutr. 2007;85:1148-56.
41. Ortega RM, Palencia A, Lopez-Sobaler AM. Improvement of cholesterol levels and reduction of cardiovascular risk via the consumption of phytosterols. Br J Nutr. 2006;96: Suppl 1:S89-93.
42. AbuMweis SS, Jones PJ. Cholesterol-lowering effect of plant sterols. Curr Atheroscler Rep. 2008;10:467-72.
43. Ripsin CM, Keenan JM, Jacobs DR Jr, Elmer PJ, Welch RR, Van Horn L, Liu K, Turnbull WH, Thye FW, et al. Oat products and lipid lowering. A meta-analysis. JAMA. 1992;267:3317-25.
44. Olson BH, Anderson SM, Becker MP, Anderson JW, Hunninghake DB, Jenkins DJ, LaRosa JC, Rippe JM, Roberts DC, et al. Psyllium-enriched cereals lower blood total cholesterol and LDL cholesterol, but not HDL cholesterol, in hypercholesterolemic adults: results of a meta-analysis. J Nutr. 1997;127:1973-80.
45. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ. 1994;308:367-72.
46. Sandberg AS. Bioavailability of minerals in legumes. Br J Nutr. 2002;88: Suppl 3:S281-5.
47. Hunt JR. Moving toward a plant-based diet: are iron and zinc at risk? Nutr Rev. 2002;60:127-34.
48. Johnson JM, Walker PM. Zinc and iron utilization in young women consuming a beef-based diet. J Am Diet Assoc. 1992;92:1474-8.
49. Lonnerdal B, Bryant A, Liu X, Theil EC. Iron absorption from soybean ferritin in nonanemic women. Am J Clin Nutr. 2006;83:103-7.
50. Murray-Kolb LE, Welch R, Theil EC, Beard JL. Women with low iron stores absorb iron from soybeans. Am J Clin Nutr. 2003;77:180-4.
51. Setchell KDR, Borriello SP, Hulme P, Kirk DN, Axelson M. Nonsteroidal estrogens of dietary origin: possible roles in hormone-dependent disease. Am J Clin Nutr. 1984;40:569-78.
52. Axelson M, Setchell KDR. The excretion of lignans in rats-evidence for an intestinal bacterial source for this new group of compounds. FEBS Lett. 1981;123:337-42.
53. Axelson M, Kirk DN, Farrant RD, Cooley G, Lawson AM, Setchell KDR. The identification of the weak oestrogen equol [7-hydroxy-3-(4′- hydroxyphenyl)chroman] in human urine. Biochem J. 1982;201:353-7.
54. Axelson M, Sjovall J, Gustafsson BE, Setchell KDR. Soya-a dietary source of the non-steroidal oestrogen equol in man and animals. J Endocrinol. 1984;102:49-55.
55. Setchell KDR, Clerici C, Lephart ED, Cole SJ, Heenan C, Castellani D, Wolfe B, Nechemias L-Z, Brown N, Baraldi G, Lund TD, Handa RJ, Heubi JE. S-Equol, a potent ligand for estrogen receptor-beta, is the exclusive enantiomeric form of the soy isoflavone metabolite produced by intestinal bacterial flora. Am J Clin Nutr. 2005;81:1072-9.
56. Lampe JW, Karr SC, Hutchins AM, Slavin JL. Urinary equol excretion with a soy challenge: influence of habitual diet. Proc Soc Exp Biol Med. 1998;217:335-9.
57. Setchell KDR, Cole SJ. Method of defining equol-producer status and its frequency among vegetarians. J Nutr. 2006;136:2188-93.
58. Setchell KDR, Clerici C, Lephart ED, Cole SJ, Heenan C, Castellani D, Wolfe BE, Nechemias-Zimmer L, Brown NM, et al. S-Equol, a potent ligand for estrogen receptor beta, is the exclusive enantiomeric form of the soy isoflavone metabolite produced by human intestinal bacterial flora. Am J Clin Nutr. 2005;81:1072-9.
59. Rowland IR, Wiseman H, Sanders TA, Adlercreutz H, Bowey EA. Interindividual variation in metabolism of soy isoflavones and lignans: influence of habitual diet on equol production by the gut microflora. Nutr Cancer. 2000;36:27-32.
60. Setchell KDR, Faughnan MS, Avades T, Zimmer-Nechemias L, Brown NM, Wolfe BE, Brashear WT, Desai P, Oldfield MF, et al. Comparing the pharmacokinetics of daidzein and genistein with the use of 13C-labeled tracers in premenopausal women. Am J Clin Nutr. 2003;77:411-9.
61. Bennetts HW, Underwood EJ, Shier FL. A specific breeding problem of sheep on subterranean clover pastures in Western Australia. Aust J Agric Res. 1946;22:131-8.
62. Brown NM, Setchell KDR. Animal models impacted by phytoestrogens in commercial chow: implications for pathways influenced by hormones. Lab Invest. 2001;81:735-47.
63. Imamov O, Lopatkin NA, Gustafsson JA. Estrogen receptor beta in prostate cancer. N Engl J Med. 2004;351:2773-4.
64. Weihua Z, Lathe R, Warner M, Gustafsson JA. An endocrine pathway in the prostate, ERbeta, AR, 5alpha-androstane-3beta,17beta-diol, and CYP7B1, regulates prostate growth. Proc Natl Acad Sci USA. 2002; 99:13589-94.
65. Muthyala RS, Ju YH, Sheng S, Williams LD, Doerge DR, Katzenellenbogen BS, Helferich WG, Katzenellenbogen JA. Equol, a natural estrogenic metabolite from soy isoflavones: convenient preparation and resolution of R- and S-equols and their differing binding and biological activity through estrogen receptors alpha and beta. Bioorg Med Chem. 2004;12:1559-67.
66. Lund TD, Munson DJ, Haldy ME, Setchell KDR, Lephart ED, Handa RJ. Equol is a novel anti-androgen that inhibits prostate growth and hormone feedback. Biol Reprod. 2004;70:1188-95.
67. Hooper L, Kroon PA, Rimm EB, Cohn JS, Harvey I, Le Cornu KA, Ryder JJ, Hall WL, Cassidy A. Flavonoids, flavonoid-rich foods, and cardiovascular risk: a meta-analysis of randomized controlled trials. Am J Clin Nutr. 2008;88:38-50.
68. Kim H, Hall P, Smith M, Kirk M, Prasain JK, Barnes S, Grubbs C. Chemoprevention by grape seed extract and genistein in carcinogen- induced mammary cancer in rats is diet dependent. J Nutr. 2004;134:3445S-52S.
69. Kim HA, Jeong KS, Kim YK. Soy extract is more potent than genistein on tumor growth inhibition. Anticancer Res. 2008;28:2837-41.